0001203311-23-000075.txt : 20230817 0001203311-23-000075.hdr.sgml : 20230817 20230817204708 ACCESSION NUMBER: 0001203311-23-000075 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230815 FILED AS OF DATE: 20230817 DATE AS OF CHANGE: 20230817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SIMPSON TODD E CENTRAL INDEX KEY: 0001216477 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-32405 FILM NUMBER: 231183594 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seagen Inc. CENTRAL INDEX KEY: 0001060736 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911874389 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21823 30TH DRIVE SE STREET 2: SUITE CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4255274000 MAIL ADDRESS: STREET 1: 21823 30TH DRIVE SE STREET 2: SUITE CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: SEATTLE GENETICS INC /WA DATE OF NAME CHANGE: 20001116 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2023-08-15 0 0001060736 Seagen Inc. SGEN 0001216477 SIMPSON TODD E 21823 30TH DRIVE SE BOTHELL WA 98021 0 1 0 0 Chief Financial Officer 1 Common Stock 2023-08-15 4 A 0 14746 0.0 A 133692 D Common Stock 2023-08-16 4 D 0 1106 193.8689 D 132586 D Common Stock 2023-08-16 4 D 0 861 193.8689 D 131725 D Common Stock 2023-08-16 4 D 0 1540 193.8689 D 130185 D These shares represent restricted stock units and will be settled in common stock upon vesting. 40% of the reporting person's annual equity award was granted in the form of performance stock units, which are not reflected here, and will be treated the same as these restricted stock units in the event the transaction with Pfizer closes. Shares shall vest at a rate of 25% on each anniversary of August 15, 2023 until all shares are fully vested at the end of four years. Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/3/2021 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/5/2020 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The sales reported in this Form 4 were effected pursuant to a written plan adopted on 10/15/2022 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). By: /s/ Jessica Nielsen Causey For: Todd E Simpson 2023-08-17